Latrunculin a has a strong anticancer effect in a peritoneal dissemination model of human gastric cancer in mice

  • Anticancer Res. 2009 Jun;29(6):2091-7.
Hiroo Konishi  1 ,  Shojiro Kikuchi ,  Toshiya Ochiai ,  Hisashi Ikoma ,  Takeshi Kubota ,  Daisuke Ichikawa ,  Hitoshi Fujiwara ,  Kazuma Okamoto ,  Chouhei Sakakura ,  Teruhisa Sonoyama ,  Yukihito Kokuba ,  Hiroyuki Sasaki ,  Takeshi Matsui ,  Eigo Otsuji
Affiliations
  • 1. Department of Surgery, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-8566, Japan.
PMID: 19528469
Abstract

Peritoneal dissemination of gastric Cancer is a refractory disease. This paper focuses on the efficacy of actin-binding marine Macrolide latrunculin A, which quickly inhibits actin polymerization and disrupts the function of the actin Cytoskeleton. The effects of latrunculin A on cell viability in vitro were evaluated by treatment of MKN45 or NUGC-4 cell cultures. An in vitro viability assay demonstrated an Anticancer effect of latrunculin A in a dose-dependent manner. Latrunculin A induced acute cell injury and programmed cell death through activating the Caspase-3/7 pathway. In vivo, MKN45 or NUGC-4 cells were intraperitoneally inoculated into nude mice, as a model of peritoneal dissemination. Intraperitoneal (i.p.) injection of latrunculin A significantly improved survival rate in mice without any major side-effects. Data indicated that latrunculin A has strong Anticancer effects, and it may be a new candidate i.p. drug against peritoneal dissemination of gastric Cancer in humans.

Products